Guggenheim Maintains Buy on Genmab, Raises Price Target to $58

Benzinga Newsdesk www.benzinga.com Positive 71.2%

Neg 0% Neu 0% Pos 71.2%

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $54 to $58.